A striking 2015 satellite image has captured a rare meteorological phenomenon known as von Kármán vortices swirling off ...

Environmental experts have lauded the Election Commission's recent decision to prohibit the use of posters in election campaigns, calling it a timely move that could curb environmental pollution and ...

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placeboPhase 3 study showed patient-reported functional benefit in ...

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 (phentolamine ophthalmic solution 0.75% ...

News PR Newswire Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions ...

It is estimated that approximately 800,000 refractive surgeries are performed in the U.S. each year, with 25% of patients suffering from visual aberrations (e.g., glare, halos, starburst) at 1-month.

8. Visual or auditory disturbances: Flashing lights, ringing, or hearing voices without a source may be linked to seizure activity rather than psychiatric illness. 9. Sudden, unexplained falls: ...

fewer visual disturbances, such as halos and glare, compared with traditional multifocal lenses improved contrast sensitivity, which helps people see more clearly in various lighting conditions ...

The Key Night Vision Disturbances Companies in the market include - Ocuphire Pharma/Viatris, and others. DelveInsight’s “Night Vision Disturbances Market Insights, Epidemiology, and Market ...

Though it is rare, visual snow syndrome is estimated to affect about 2% to 3% of the global population. In a 2020 study involving 1,100 people with the condition, the average age of participants ...